Peninsula company stock soars as it plots approval of rare liver disease drug
Mirum Pharmaceuticals will start filing paperwork in third-quarter 2020 for FDA approval of its drug in children with Alagille syndrome.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Children | Health Management | Liver | Liver Disease | Pharmaceuticals | Urology & Nephrology